Drug–Drug Interaction Studies

Author(s):  
Wolfgang Schmider ◽  
Xavier Boulenc
2014 ◽  
Vol 29 (3) ◽  
Author(s):  
Yu-Yuan Chiu ◽  
Larry Ereshefsky ◽  
Sheldon H. Preskorn ◽  
Nagaraju Poola ◽  
Antony Loebel

2020 ◽  
Vol 45 (4) ◽  
pp. 433-444
Author(s):  
Roland Heinig ◽  
Michael Gerisch ◽  
Michaela Bairlein ◽  
Johannes Nagelschmitz ◽  
Stephanie Loewen

2019 ◽  
Vol 21 (5) ◽  
Author(s):  
Andrea Treyer ◽  
Mohammed Ullah ◽  
Neil Parrott ◽  
Birgit Molitor ◽  
Stephen Fowler ◽  
...  

Bioanalysis ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 569-582
Author(s):  
Peng Guo ◽  
Qiucheng Liang ◽  
Juntao Zheng ◽  
Jinmin Chen ◽  
Yanping Guan ◽  
...  

Aim: Heart failure patients are frequently given comedication of digoxin and diuretics like spironolactone and tolvaptan. A UHPLC–MS/MS assay for determining canrenone (main active metabolite of spironolactone), digoxin and tolvaptan simultaneously should be developed so as to support related drug–drug interaction studies. Results: A UHPLC–MS/MS method for simultaneous determination of these three drugs in human plasma was established and fully verified as per CFDA guidelines. Chromatographic separation was achieved using a 4-min isocratic elution. Mass analyses were performed under positive electrospray ionization mode. The calibration curves were established over 1.0–400.0 ng/ml for canrenone and tolvaptan while over 0.1–40.0 ng/ml for digoxin. Conclusion: The developed method was feasible in detecting concentration and related drug–drug interaction studies.


Sign in / Sign up

Export Citation Format

Share Document